# 2025年12月24日 - 专业文献速递

本期速递为您整理了最新的科研文献及AI评价，每一篇文献都包含了详细的元数据、原文摘要、中文翻译和AI的专业点评，敬请参考。

---

## 1. 同步辐射产生的微束作为耐药性癫痫的放射外科替代方案：基于小鼠内侧颞叶癫痫模型的概念验证研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41432569)
**期刊：** Epilepsia
**PMID：** 41432569
**DOI：** 10.1002/epi.70063

### 第一部分 原文与翻译

**英文原标题：** Synchrotron-generated microbeams as a radiosurgical alternative for drug-resistant epilepsies: Proof of concept in a mouse model of mesiotemporal lobe epilepsy.

> **英文摘要：**
> OBJECTIVE: One-third of patients with epilepsy, particularly those with mesial temporal lobe epilepsy (MTLE), remain resistant to medication. Resective surgery, the gold standard, is highly invasive and carries significant risks. Here, using a mouse model, we explored the potential of microbeam radiation therapy (MRT), a new technique based on the spatial microfractionation of high-flux X-rays, as a non-invasive alternative for treating MTLE.
> 
> METHODS: MTLE was modeled in male C57BL6/J mice via unilateral kainate injection in the dorsal hippocampus. Mice with magnetic resonance imaging (MRI)-validated hippocampal sclerosis (HS) were irradiated at the European Synchrotron Radiation Facility (ESRF) using MRT with either a single trajectory (peak doses = 125-500 Gy) or multiple trajectories (2 or 5 ports at a cumulated peak dose of 125 Gy at the target). Their focal seizures were then monitored with use of electroencephalography (EEG) during 8 weeks, upon which immunochemistry was performed to assess potential tissular toxicity.
> 
> RESULTS: Anteroposterior 1-port MRT significantly reduced EEG-recorded focal seizures at 125 and 250 Gy, in a dose-dependent manner. However, increased mortality was observed at 500 Gy. Immunohistolabeling revealed neuronal loss (revealed by NeuN staining), microgliosis (revealed by Iba1 straining), and astrogliosis (revealed by GFAP staining) limited to the microbeam tracks at all doses in the injected hippocampus and adjacent brain structures (e.g., cortex). Five-port MRT with a peak dose of 125 Gy at the target improved the antiepileptic effect, whereas no significant tissue alterations outside the microbeam tracks were detected by histological assessment.
> 
> SIGNIFICANCE: This proof-of-concept study highlights MRT as a promising non-invasive therapy for drug-resistant focal epilepsies with optimal peak doses of 125-250 Gy, and it suggests that distributing the dose through multiple angles optimizes the therapeutic effect. MRT could provide a safer alternative to surgery, warranting further investigations.

> **中文摘要：**
> 研究目的：约有三分之一的癫痫患者，尤其是内侧颞叶癫痫（MTLE）患者，对药物治疗仍然耐受。切除性手术虽然被视为金标准，但具有高度侵入性并伴随显著风险。本研究利用小鼠模型探索了微束放射治疗（MRT）的潜力，这是一种基于高通量 X 射线空间微分化的新技术，作为治疗 MTLE 的非侵入性替代方案。
> 
> 研究方法：通过向雄性 C57BL6/J 小鼠背侧海马单侧注射卡因酸建立 MTLE 模型。经磁共振成像（MRI）验证存在海马硬化（HS）的小鼠在欧洲同步辐射设施（ESRF）接受 MRT 照射，照射方式包括单轨（峰剂量为 125–500 Gy）或多轨（2 或 5 个入射口，总峰剂量为靶区 125 Gy）。随后使用脑电图（EEG）监测 8 周的局灶性癫痫发作，并进行免疫化学评估以检测潜在的组织毒性。
> 
> 研究结果：前后向单入射口 MRT 在 125 和 250 Gy 剂量下可明显剂量依赖性地减少脑电图记录的局灶性癫痫发作，但在 500 Gy 时观察到死亡率升高。免疫组织标记显示，所有剂量下注射侧海马及邻近脑结构（如皮质）中，神经元丢失（NeuN 染色）、小胶质增生（Iba1 染色）及星形胶质增生（GFAP 染色）均仅限于微束轨迹区域。采用 125 Gy 峰剂量且 5 个入射口的 MRT 能增强抗癫痫效果，而组织学评估未发现微束轨迹之外区域存在显著的组织改变。
> 
> 研究意义：该概念验证研究表明，MRT 是一种有望用于治疗耐药性局灶性癫痫的非侵入性疗法，其最佳峰剂量为 125–250 Gy，并提示通过多角度分布剂量可优化治疗效果。MRT 有望成为安全性更高的手术替代方案，值得进一步研究。

### 第二部分 AI 大师评价

本研究基于小鼠内侧颞叶癫痫模型，验证了微束放射治疗（MRT）在耐药性局灶性癫痫中的可行性与初步疗效。研究通过同步辐射装置精确控制微束轨迹与剂量，揭示出125–250 Gy峰剂量在降低癫痫发作方面具剂量依赖性。多入射角的MRT可强化抗癫痫效应且未观察到显著组织损伤，显示其潜在安全性与精准性。创新之处在于首次将空间微分化高通量X射线引入癫痫放射外科领域，但仍受限于动物模型及长期随访不足。

---

## 2. 血清S100钙结合蛋白β（S100B）作为创伤性脑损伤后癫痫的生物标志物：丹麦成年人基于登记的队列研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41432378)
**期刊：** Epilepsia
**PMID：** 41432378
**DOI：** 10.1002/epi.70049

### 第一部分 原文与翻译

**英文原标题：** S100 calcium-binding protein beta (S100B) in serum as a biomarker for epilepsy after traumatic brain injury: A register-based cohort study in Danish adults.

> **英文摘要：**
> OBJECTIVE: This study was undertaken to evaluate whether elevated serum levels of S100 calcium-binding protein beta (S100B) provide a prognostic biomarker for the development of epilepsy after traumatic brain injury (TBI).
> 
> METHODS: We conducted a register-based cohort study in adults (≥18 years of age) who presented to Danish emergency departments between 2013 and 2022 with a head injury and underwent serum S100B sampling. We classified injury severity hierarchically according to TBI diagnoses (No TBI, mild TBI without [mTBI-] and with [mTBI+] detectable lesions) recorded the first week after injury admission. Epilepsy onset was set to the date of the first epilepsy diagnosis or first redeemed antiseizure medication prescription after TBI. Persons were followed until epilepsy onset, death, or December 31, 2022, whichever came first. We estimated hazard ratios (HRs) and absolute risk (AR) of epilepsy according to S100B levels with corresponding 95% confidence intervals (CIs), according to injury severity, age, sex, and multimorbidity.
> 
> RESULTS: Mean serum S100B levels increased with TBI severity (p < .0001). A 1-unit S100B increase (in μg/L) after TBI carried increased epilepsy risk (HR = 1.46, 95% CI = 1.20-1.77), but only in mTBI+ patients (HR = 2.12, 95% CI = 1.55-2.92). The overall 5-year AR of epilepsy after any head injury was 3.8% (95% CI = 1.5%-7.8%), 2.0% (95% CI = 1.2%-3.1%), and 1.0% (95% CI = .8%-1.3%) in patients with S100B levels of 2.0, 1.0, and .1 μg/L, respectively, and in the subgroup of mTBI+ patients the ARs were 21.3% (95% CI = 9.0%-38.2%), 5.7% (95% CI = 2.6%-10.6%), and .8% (95% CI = .2%-2.4%). Age and sex had minor influence on the association, but having a high multimorbidity score (HR = 2.03, 95% CI = 1.28-3.23) was a pivotal modifier, rendering the association insignificant in those without (HR = 1.21, 95% CI = 0.88-1.67).
> 
> SIGNIFICANCE: Elevated serum S100B levels after TBI were associated with subsequent epilepsy, likely reflecting the extent of intracranial injury. Despite study limitations, these findings support the potential of S100B as a prognostic biomarker.

> **中文摘要：**
> 研究目的：本研究旨在评估血清S100钙结合蛋白β（S100B）升高是否可作为创伤性脑损伤（TBI）后癫痫发生的预后生物标志物。
> 
> 研究方法：我们开展了一项基于登记的队列研究，纳入2013年至2022年间在丹麦急诊科因头部损伤就诊并接受血清S100B检测的成年人（≥18岁）。根据TBI诊断分级（无TBI、无影像学病变的轻度TBI [mTBI−]及有可检出病变的轻度TBI [mTBI+]），以入院后第一周的记录确定损伤严重程度。癫痫发作时间定义为TBI后首次癫痫诊断或首次购药抗癫痫药处方的日期。研究对象随访至癫痫发作、死亡或2022年12月31日，以先发生者为终点。我们依据S100B水平及其95%置信区间（CI），结合损伤严重程度、年龄、性别及多病共存情况，估算癫痫的风险比（HR）和绝对风险（AR）。
> 
> 研究结果：血清S100B平均水平随TBI严重程度增加而升高（p < 0.0001）。TBI后S100B每升高1个单位（μg/L）均与癫痫风险增加相关（HR = 1.46, 95% CI = 1.20–1.77），但仅在mTBI+患者中显著（HR = 2.12, 95% CI = 1.55–2.92）。在任何头部损伤后，S100B水平分别为2.0、1.0及0.1 μg/L的患者5年癫痫绝对风险分别为3.8%（95% CI = 1.5%–7.8%）、2.0%（95% CI = 1.2%–3.1%）及1.0%（95% CI = 0.8%–1.3%）；在mTBI+亚组中，上述风险分别为21.3%（95% CI = 9.0%–38.2%）、5.7%（95% CI = 2.6%–10.6%）及0.8%（95% CI = 0.2%–2.4%）。年龄与性别对该关联影响较小，但高多病共存评分显著增强该关系（HR = 2.03, 95% CI = 1.28–3.23），在无多病共存者中则无统计学意义（HR = 1.21, 95% CI = 0.88–1.67）。
> 
> 研究意义：TBI后血清S100B水平升高与后续癫痫发作相关，可能反映了颅内损伤的程度。尽管存在研究局限，该结果支持S100B作为癫痫预后生物标志物的潜力。

### 第二部分 AI 大师评价

本研究通过全国登记数据库，对TBI后癫痫风险与血清S100B水平的关系进行了系统量化，发现S100B升高尤其在存在影像学病变的轻度TBI患者中与癫痫风险显著相关。研究利用大样本、长期随访和多因素调整，提供了S100B作为预后标志物的重要证据。其创新性在于将实验室生物标志物与临床诊断数据库结合，揭示了S100B的分层预后价值。局限性在于队列数据中潜在的测量偏倚及因果推断限制。

---

## 3. 清除衰老细胞可改善小鼠颞叶癫痫及相关空间记忆缺陷

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41428987)
**期刊：** Annals of neurology
**PMID：** 41428987
**DOI：** 10.1002/ana.78118

### 第一部分 原文与翻译

**英文原标题：** Senescent Cell Clearance Ameliorates Temporal Lobe Epilepsy and Associated Spatial Memory Deficits in Mice.

> **英文摘要：**
> OBJECTIVE: The pharmacological treatment of temporal lobe epilepsy (TLE), a disorder characterized by recurrent seizures and cognitive dysfunction, is limited to symptomatic control. Identifying novel targets to modify disease progression is of great clinical and translational interest. Cellular senescence has been recently implicated in the development and progression of other neurodegenerative diseases, but its role in TLE is unstudied.
> 
> METHODS: We first investigated cellular senescence markers in resected hippocampi from patients with medically intractable TLE through multiplexed immunofluorescence. We next used a mouse model of TLE (pilocarpine induced status epilepticus [SE]) for a combination of immunohistochemistry, behavioral testing, and electroencephalogram (EEG) monitoring. We implemented 2 strategies for removal of senescent cells (SCs), a genetic mouse model allowing for targeted senolysis, and a pharmacological approach using dasatinib and quercetin.
> 
> RESULTS: We found a 5-fold elevation of senescent glia in human TLE cases as compared with controls. In mice, we found increases in senescence markers at both the transcript and protein level and predominantly expressed in microglia, which developed within 2 weeks following SE. Senolytic treatment produced a 50% reduction in SCs, rescued long-term potentiation deficits, normalized spatial memory impairments, reduced seizures, and protected a third of animals from epilepsy.
> 
> INTERPRETATION: Our data demonstrate that SCs accumulate in both human TLE and in a mouse model of TLE and suggest that clearing SCs may be a viable strategy to reduce seizures and associated cognitive comorbidities. ANN NEUROL 2025.

> **中文摘要：**
> 研究目的：颞叶癫痫（TLE）是一种以反复发作和认知功能障碍为特征的疾病，其药物治疗局限于症状控制。确定可改变疾病进程的新靶点具有重要的临床和转化意义。细胞衰老最近在其他神经退行性疾病的发生和进展中被证明具有一定作用，但其在TLE中的作用尚未研究。
> 
> 研究方法：我们首先通过多重免疫荧光技术检测了难治性TLE患者切除海马中的细胞衰老标志物。随后，在小鼠TLE模型（匹罗卡品诱导的癫痫持续状态[SE]）中，结合免疫组织化学、行为学测试和脑电图（EEG）监测。我们采取了两种清除衰老细胞（SCs）的策略：一种是利用可进行靶向清除的遗传小鼠模型，另一种是采用达沙替尼和槲皮素的药理方法。
> 
> 研究结果：与对照组相比，人类TLE病例中衰老胶质细胞增加了5倍。在小鼠中，我们发现转录和蛋白水平的衰老标志物均升高，主要表达于小胶质细胞中，并在SE后2周内形成。去衰老治疗使SCs减少约50%，恢复了长时程增强（LTP）缺陷，纠正了空间记忆障碍，减少了癫痫发作，并使三分之一的小鼠免于癫痫。
> 
> 研究结论：我们的数据表明，SCs在人体TLE和小鼠TLE模型中均积累，提示清除衰老细胞可能是一种减少癫痫发作及相关认知共病的可行策略。

### 第二部分 AI 大师评价

本研究将细胞衰老机制与颞叶癫痫的病理生理联系起来，通过人类组织学分析与小鼠模型实验相结合，揭示衰老细胞在TLE中的显著积累及其功能影响。研究证明清除衰老细胞能够改善癫痫频率和认知损伤，显示出潜在的治疗新方向。方法学上兼顾遗传和药理学策略，证据链完整。虽然研究主要基于动物模型，仍需进一步验证其在临床中的可行性和长期安全性。

---

速递结束，祝您工作愉快！